Index RUT
P/E -
EPS (ttm) -2.92
Insider Own 21.83%
Shs Outstand 96.79M
Perf Week 1.63%
Market Cap 937.66M
Forward P/E -
EPS next Y -1.24
Insider Trans -0.53%
Shs Float 90.50M
Perf Month 1.38%
Income -217.42M
PEG -
EPS next Q -0.52
Inst Own 98.51%
Short Float 27.23%
Perf Quarter -26.76%
Sales 106.39M
P/S 8.81
EPS this Y 55.07%
Inst Trans 9.75%
Short Ratio 7.76
Perf Half Y 299.01%
Book/sh 1.95
P/B 4.16
EPS next Y 27.09%
ROA -
Short Interest 24.64M
Perf Year -20.67%
Cash/sh 3.49
P/C 2.32
EPS next 5Y 9.80%
ROE -
52W Range 1.76 - 13.17
Perf YTD 150.77%
Dividend Est. -
P/FCF -
EPS past 5Y -48.07%
ROI -50.45%
52W High -38.50%
Beta 1.16
Dividend TTM -
Quick Ratio 9.61
Sales past 5Y 303.42%
Gross Margin 92.35%
52W Low 360.23%
ATR (14) 0.62
Dividend Ex-Date -
Current Ratio 9.89
EPS Y/Y TTM 48.42%
Oper. Margin -184.65%
RSI (14) 45.81
Volatility 5.85% 7.46%
Employees 296
Debt/Eq 0.92
Sales Y/Y TTM -
Profit Margin -204.36%
Recom 1.33
Target Price 19.00
Option/Short Yes / Yes
LT Debt/Eq 0.92
EPS Q/Q 73.03%
Payout -
Rel Volume 0.57
Prev Close 7.78
Sales Surprise 226.65%
EPS Surprise 53.28%
Sales Q/Q 1574.06%
Earnings May 14 AMC
Avg Volume 3.18M
Price 8.10
SMA20 -5.46%
SMA50 -10.91%
SMA200 27.78%
Trades
Volume 1,827,856
Change 4.11%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-03-24 Upgrade
Mizuho
Neutral → Buy
$4 → $8
Oct-26-23 Downgrade
Mizuho
Buy → Neutral
$57 → $4
Oct-13-23 Downgrade
Goldman
Buy → Neutral
$32 → $6
Sep-07-22 Initiated
Needham
Buy
$46
Mar-17-22 Initiated
Goldman
Buy
$45
Jun-30-21 Initiated
Mizuho
Buy
$58
May-27-21 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$52
Nov-09-20 Upgrade
Goldman
Neutral → Buy
$34 → $36
Oct-08-20 Initiated
Truist
Buy
$38
Feb-25-20 Initiated
Guggenheim
Buy
$36
Feb-25-20 Initiated
Goldman
Neutral
$30
Feb-25-20 Initiated
Cowen
Outperform
$55
Feb-25-20 Initiated
Cantor Fitzgerald
Overweight
$50
Show Previous Ratings
Jun-10-24 02:30PM
Jun-05-24 04:00PM
08:00AM
Jun-03-24 08:00AM
May-31-24 09:40AM
09:55AM
Loading…
May-20-24 09:55AM
May-16-24 11:23AM
May-15-24 12:54PM
(Thomson Reuters StreetEvents) +13.65%
12:03PM
09:12AM
08:53AM
08:46AM
08:19AM
07:29AM
04:24AM
03:13AM
Loading…
03:13AM
May-14-24 08:57PM
04:53PM
04:00PM
May-13-24 08:00AM
May-03-24 04:00PM
Apr-29-24 04:00PM
Apr-10-24 08:00AM
Apr-05-24 04:00PM
Apr-01-24 07:00AM
Mar-28-24 08:00AM
Mar-19-24 09:55AM
Mar-18-24 09:55AM
Mar-11-24 08:00AM
Mar-10-24 04:00PM
04:00PM
Loading…
Mar-09-24 04:00PM
Mar-08-24 07:33PM
Mar-05-24 04:00PM
Mar-04-24 04:00PM
08:00AM
Mar-01-24 09:55AM
09:40AM
Feb-29-24 05:00PM
11:33AM
Feb-28-24 11:30PM
04:10PM
04:00PM
12:16AM
(Thomson Reuters StreetEvents)
Feb-27-24 08:11AM
05:50AM
Feb-16-24 08:00AM
Feb-06-24 04:00PM
Feb-01-24 03:04PM
Jan-31-24 08:00AM
Jan-29-24 08:00AM
Jan-22-24 08:00AM
Jan-18-24 12:00PM
Jan-14-24 04:00AM
04:00AM
Dec-23-23 07:32PM
Dec-19-23 11:48AM
Dec-18-23 06:02AM
(Pharmaceutical Business Review)
04:58AM
Dec-15-23 05:19PM
05:14PM
05:11PM
Dec-01-23 10:00PM
Nov-29-23 08:00AM
Nov-17-23 09:35AM
Nov-16-23 11:04PM
Nov-15-23 01:26PM
Nov-14-23 05:04PM
Nov-05-23 03:55PM
Nov-03-23 09:47AM
07:30AM
Nov-02-23 04:00PM
Nov-01-23 09:35AM
Oct-31-23 09:35AM
Oct-26-23 12:32PM
(The Wall Street Journal)
Oct-25-23 04:00PM
Oct-20-23 08:00AM
Oct-19-23 11:45PM
04:04PM
Oct-13-23 08:00AM
Oct-09-23 08:52AM
Oct-06-23 08:00AM
Oct-05-23 04:00PM
Sep-27-23 08:00AM
04:16AM
Sep-25-23 04:17PM
09:00AM
Sep-19-23 07:30AM
Sep-15-23 04:00PM
Sep-13-23 08:32AM
Sep-12-23 07:30AM
Sep-07-23 03:08PM
08:15AM
Sep-05-23 04:00PM
Aug-31-23 10:12PM
10:33AM
08:00AM
Aug-29-23 08:00AM
Aug-18-23 04:30PM
Aug-13-23 08:08AM
Aug-11-23 06:02AM
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Welgus Howard G. Director Jun 04 '24 Option Exercise 1.68 10,000 16,806 180,200 Jun 06 04:15 PM Welgus Howard G. Director Jun 04 '24 Sale 8.01 10,000 80,092 170,200 Jun 06 04:15 PM Burnett Patrick See Remarks May 30 '24 Option Exercise 0.00 23,000 0 232,793 May 31 04:50 PM Burnett Patrick See Remarks May 30 '24 Sale 8.75 23,000 201,319 209,793 May 31 04:50 PM Burnett Patrick See Remarks May 29 '24 Sale 8.72 49,952 435,387 209,793 May 31 04:50 PM Matsuda Masaru See Remark May 28 '24 Sale 9.01 1,775 15,988 188,508 May 29 07:38 PM Edwards Larry Todd SVP Chief Commercial Officer May 17 '24 Sale 8.98 7,640 68,582 140,360 May 20 05:12 PM Watanabe Todd Franklin See Remarks May 02 '24 Sale 8.74 13,783 120,433 860,750 May 03 04:22 PM Burnett Patrick See Remarks May 02 '24 Sale 8.74 9,555 83,490 259,745 May 03 04:22 PM Matsuda Masaru See Remark May 02 '24 Sale 8.74 5,016 43,829 185,408 May 03 04:22 PM Moore Matthew Richard SVP and Chief Business Officer May 02 '24 Sale 8.74 4,681 40,902 145,505 May 03 04:29 PM Heron Patrick J Director Mar 04 '24 Buy 9.50 21,052 199,994 8,785,284 Mar 06 04:28 PM Watanabe Todd Franklin See Remarks Mar 04 '24 Sale 11.12 14,903 165,739 874,533 Mar 06 05:09 PM Burnett Patrick See Remarks Mar 04 '24 Sale 11.12 4,782 53,182 269,300 Mar 06 05:12 PM Matsuda Masaru See Remark Mar 04 '24 Sale 11.12 3,760 41,816 190,424 Mar 06 05:14 PM Moore Matthew Richard SVP and Chief Business Officer Mar 04 '24 Sale 11.12 3,468 38,568 146,020 Mar 06 05:08 PM Watanabe Todd Franklin See Remarks Feb 28 '24 Sale 10.60 2,465 26,129 889,436 Mar 01 04:11 PM Burnett Patrick See Remarks Jan 02 '24 Sale 3.54 1,325 4,692 57,032 Jan 03 05:30 PM Watanabe Todd Franklin See Remarks Dec 01 '23 Option Exercise 1.68 59,525 100,038 513,682 Dec 01 08:51 PM Matsuda Masaru See Remark Nov 21 '23 Sale 1.98 1,850 3,661 46,634 Nov 21 05:47 PM Frazier Life Sciences VIII, L. 10% Owner Oct 24 '23 Buy 2.50 80,000 200,000 8,764,232 Oct 26 04:09 PM Burnett Patrick See Remarks Aug 21 '23 Sale 7.04 1,605 11,302 58,357 Aug 22 12:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite